SUPN - Supernus Pharmaceuticals GAAP EPS of -$0.29 in-line revenue of $153.88M beats by $10.49M
2023-11-08 16:39:44 ET
More on Supernus Pharmaceuticals
- Supernus: Product Sales Stretching Higher, But Not Reflected In Economic Leverage
- Supernus Pharmaceuticals Q3 2023 Earnings Preview
- Supernus resubmits NDA for Parkinson's disease infusion device
- Seeking Alpha’s Quant Rating on Supernus Pharmaceuticals
- Historical earnings data for Supernus Pharmaceuticals
For further details see:
Supernus Pharmaceuticals GAAP EPS of -$0.29 in-line, revenue of $153.88M beats by $10.49M